Gene Silencing Market
Gene Silencing Market Forecasts to 2032 – Global Analysis By Product & Service (Reagents, Kits, Instruments, Oligonucleotides & RNA Molecules, Software & Bioinformatics Tools, Gene Silencing Services and Other Product & Services), Mechanism, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Gene Silencing Market is accounted for $11.48 billion in 2025 and is expected to reach $32.07 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Gene silencing is a natural biological process that regulates gene expression by preventing specific genes from producing proteins or other gene products. It can occur at the transcriptional or post-transcriptional level, effectively “turning off” a gene without altering its DNA sequence. Mechanisms such as RNA interference (RNAi), DNA methylation, and histone modification play key roles in this process. Gene silencing helps control cellular functions, maintain genome stability, and defend against viruses or transposable elements. It is also widely used in biotechnology and medicine for studying gene function and developing treatments for genetic and infectious diseases.
Market Dynamics:
Driver:
Rising prevalence of genetic & chronic diseases
RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based silencing platforms enable targeted modulation of disease-causing genes. Pharmaceutical firms and biotech startups are scaling silencing pipelines to address conditions such as Huntington’s, ALS, and hereditary cancers. Integration with genomic profiling and delivery systems enhances therapeutic precision and tissue targeting. Demand for non-invasive and durable interventions is rising across personalized medicine and orphan drug programs. These dynamics are propelling platform innovation and clinical adoption across gene silencing ecosystems.
Restraint:
Safety and immunogenicity concerns
Off-target effects, immune activation, and toxicity risks degrade platform reliability and patient outcomes. Delivery vehicles such as viral vectors and lipid nanoparticles must balance efficacy with biocompatibility and clearance. Regulatory bodies require extensive preclinical validation and long-term safety data to approve silencing candidates. Clinical trial delays and adverse event reporting continue to hinder investor confidence and pipeline progression. These constraints are hampering adoption across high-risk and immunologically sensitive therapeutic areas.
Opportunity:
Successful clinical proof-of-concept and approvals
FDA and EMA approvals of RNAi-based drugs such as patisiran and givosiran validate therapeutic efficacy and commercial viability. Clinical trials demonstrate durable gene knockdown, symptom reduction, and biomarker improvement across rare and chronic conditions. Expansion into oncology, metabolic, and infectious disease indications is accelerating across academic and industry sponsors. Demand for scalable and regulatory-aligned silencing platforms is rising across pharma partnerships and licensing deals. These trends are fostering growth across clinical translation and therapeutic diversification.
Threat:
Intellectual property & market competition
Patent disputes, licensing restrictions, and freedom-to-operate challenges constrain innovation and market entry. Dominance of early movers and proprietary delivery systems limits access for emerging players and academic spinouts. Fragmented IP landscapes complicate cross-border commercialization and strategic alliances. Competitive pressure from CRISPR, base editing, and epigenetic modulation platforms reduces investor focus on traditional silencing modalities. These risks continue to limit platform scalability and long-term positioning across therapeutic markets.
Covid-19 Impact:
The pandemic disrupted clinical trials, manufacturing, and regulatory timelines across gene silencing programs. Lockdowns and resource reallocation delayed patient recruitment and data collection across rare disease and oncology trials. However, interest in RNA-based platforms surged due to mRNA vaccine success and public awareness of genetic medicine. Investment in delivery systems, immunogenicity mitigation, and remote monitoring accelerated platform innovation. Post-pandemic strategies now include gene silencing as a core pillar of precision medicine and therapeutic resilience. These shifts are reinforcing long-term investment and regulatory engagement across silencing technologies.
The RNA interference (RNAi) segment is expected to be the largest during the forecast period
The RNA interference (RNAi) segment is expected to account for the largest market share during the forecast period due to its validated mechanism, clinical maturity, and broad applicability across disease areas. RNAi platforms use siRNA and shRNA constructs to silence target genes with high specificity and durability. Integration with lipid nanoparticle delivery and tissue-specific promoters enhances therapeutic precision and safety. Approved RNAi drugs and late-stage candidates demonstrate efficacy across liver, nerve, and ocular indications. Demand for scalable and modular RNAi platforms is rising across pharma pipelines and academic research.
The software & bioinformatics tools segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the software & bioinformatics tools segment is predicted to witness the highest growth rate as data complexity and target validation drive demand for advanced analytics. Platforms support sequence design, off-target prediction, and delivery optimization across RNAi, ASO, and CRISPR workflows. AI and machine learning algorithms enable biomarker discovery, toxicity modelling, and patient stratification across clinical cohorts. Cloud-based infrastructure and modular pipelines improve scalability and accessibility across research and commercial environments. Demand for interoperable, secure, and clinically validated bioinformatics tools is rising across silencing development and regulatory submission.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech ecosystem, regulatory clarity, and clinical infrastructure. U.S. and Canadian firms deploy gene silencing platforms across rare disease, oncology, and neurology programs with integrated delivery and analytics. Investment in genomic medicine, academic-industry partnerships, and FDA engagement supports platform scalability and validation. Presence of leading therapeutic developers, CROs, and research institutions drives innovation and standardization. These factors are propelling North America’s leadership in gene silencing commercialization and clinical translation.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, genetic disease burden, and biotech investment converge across regional economies. Countries like China, India, Japan, and South Korea scale gene silencing platforms across public health programs, academic research, and clinical trials. Government-backed initiatives support infrastructure development, startup incubation, and international collaboration across RNA and oligonucleotide therapeutics. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. These trends are accelerating regional growth across gene silencing innovation and therapeutic deployment.
Key players in the market
Some of the key players in Gene Silencing Market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Sirnaomics, Arbutus Biopharma, Olix Pharmaceuticals, Benitec Biopharma, Sylentis, Genevant Sciences, RXi Pharmaceuticals, Intellia Therapeutics, Editas Medicine and Beam Therapeutics.
Key Developments:
In September 2025, Ionis secured FDA approvals for TRYNGOLZA (for familial chylomicronemia syndrome, FCS) and DAWNZERA (for hereditary angioedema, HAE), marking a pivotal commercial milestone. Clinical trials showed 72% triglyceride reduction and 85% fewer pancreatitis events for olezarsen, the active compound in TRYNGOLZA. These approvals validate Ionis’ RNA-targeted platform and expand its rare disease portfolio.
In February 2025, Alnylam unveiled its TRITON Phase 3 program for nucresiran, a next-generation TTR silencer targeting ATTR-CM and hATTR-PN. The candidate builds on Alnylam’s RNAi leadership in amyloidosis and aims to deliver durable knockdown with improved delivery. It complements the company’s existing portfolio and supports long-term franchise sustainability in rare diseases.
Product & Services Covered:
• Reagents & Kits
• Instruments
• Oligonucleotides & RNA Molecules
• Software & Bioinformatics Tools
• Gene Silencing Services
• Other Product & Services
Mechanisms Covered:
• Transcriptional Gene Silencing
• Post-Transcriptional Gene Silencing
• Epigenetic Modulation
Technologies Covered:
• RNA Interference (RNAi)
• Antisense Oligonucleotides (ASOs)
• CRISPR Interference (CRISPRi)
• Epigenetic Silencing
• siRNA/shRNA Delivery Systems
Applications Covered:
• Drug Discovery & Development
• Therapeutics Manufacturing
• Functional Genomics
• Target Validation
• Disease Modeling
• Other Applications
End Users Covered:
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• CROs & CDMOs
• Hospitals & Diagnostic Labs
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Gene Silencing Market, By Product & Service
5.1 Introduction
5.2 Reagents & Kits
5.3 Instruments
5.4 Oligonucleotides & RNA Molecules
5.5 Software & Bioinformatics Tools
5.6 Gene Silencing Services
5.7 Other Product & Services
6 Global Gene Silencing Market, By Mechanism
6.1 Introduction
6.2 Transcriptional Gene Silencing
6.3 Post-Transcriptional Gene Silencing
6.4 Epigenetic Modulation
7 Global Gene Silencing Market, By Technology
7.1 Introduction
7.2 RNA Interference (RNAi)
7.3 Antisense Oligonucleotides (ASOs)
7.4 CRISPR Interference (CRISPRi)
7.5 Epigenetic Silencing
7.6 siRNA/shRNA Delivery Systems
8 Global Gene Silencing Market, By Application
8.1 Introduction
8.2 Drug Discovery & Development
8.3 Therapeutics Manufacturing
8.4 Functional Genomics
8.5 Target Validation
8.6 Disease Modeling
8.7 Other Applications
9 Global Gene Silencing Market, By End User
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Academic & Research Institutions
9.4 CROs & CDMOs
9.5 Hospitals & Diagnostic Labs
9.6 Other End Users
10 Global Gene Silencing Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Alnylam Pharmaceuticals
12.2 Ionis Pharmaceuticals
12.3 Arrowhead Pharmaceuticals
12.4 Silence Therapeutics
12.5 Dicerna Pharmaceuticals
12.6 Sirnaomics
12.7 Arbutus Biopharma
12.8 Olix Pharmaceuticals
12.9 Benitec Biopharma
12.10 Sylentis
12.11 Genevant Sciences
12.12 RXi Pharmaceuticals
12.13 Intellia Therapeutics
12.14 Editas Medicine
12.15 Beam Therapeutics
List of Tables
1 Global Gene Silencing Market Outlook, By Region (2024-2032) ($MN)
2 Global Gene Silencing Market Outlook, By Product & Service (2024-2032) ($MN)
3 Global Gene Silencing Market Outlook, By Reagents & Kits (2024-2032) ($MN)
4 Global Gene Silencing Market Outlook, By Instruments (2024-2032) ($MN)
5 Global Gene Silencing Market Outlook, By Oligonucleotides & RNA Molecules (2024-2032) ($MN)
6 Global Gene Silencing Market Outlook, By Software & Bioinformatics Tools (2024-2032) ($MN)
7 Global Gene Silencing Market Outlook, By Gene Silencing Services (2024-2032) ($MN)
8 Global Gene Silencing Market Outlook, By Other Product & Services (2024-2032) ($MN)
9 Global Gene Silencing Market Outlook, By Mechanism (2024-2032) ($MN)
10 Global Gene Silencing Market Outlook, By Transcriptional Gene Silencing (2024-2032) ($MN)
11 Global Gene Silencing Market Outlook, By Post-Transcriptional Gene Silencing (2024-2032) ($MN)
12 Global Gene Silencing Market Outlook, By Epigenetic Modulation (2024-2032) ($MN)
13 Global Gene Silencing Market Outlook, By Technology (2024-2032) ($MN)
14 Global Gene Silencing Market Outlook, By RNA Interference (RNAi) (2024-2032) ($MN)
15 Global Gene Silencing Market Outlook, By Antisense Oligonucleotides (ASOs) (2024-2032) ($MN)
16 Global Gene Silencing Market Outlook, By CRISPR Interference (CRISPRi) (2024-2032) ($MN)
17 Global Gene Silencing Market Outlook, By Epigenetic Silencing (2024-2032) ($MN)
18 Global Gene Silencing Market Outlook, By siRNA/shRNA Delivery Systems (2024-2032) ($MN)
19 Global Gene Silencing Market Outlook, By Application (2024-2032) ($MN)
20 Global Gene Silencing Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
21 Global Gene Silencing Market Outlook, By Therapeutics Manufacturing (2024-2032) ($MN)
22 Global Gene Silencing Market Outlook, By Functional Genomics (2024-2032) ($MN)
23 Global Gene Silencing Market Outlook, By Target Validation (2024-2032) ($MN)
24 Global Gene Silencing Market Outlook, By Disease Modeling (2024-2032) ($MN)
25 Global Gene Silencing Market Outlook, By Other Applications (2024-2032) ($MN)
26 Global Gene Silencing Market Outlook, By End User (2024-2032) ($MN)
27 Global Gene Silencing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
28 Global Gene Silencing Market Outlook, By Academic & Research Institutions (2024-2032) ($MN)
29 Global Gene Silencing Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
30 Global Gene Silencing Market Outlook, By Hospitals & Diagnostic Labs (2024-2032) ($MN)
31 Global Gene Silencing Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
